Breaking News Headlines Today | Ground News

See every side of every news story

urologytimes.com image

News from urologytimes.com

We’ve assigned a media bias rating of unknown to urologytimes.com. You can read more about our methodology here.

urologytimes.com’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about urologytimes.com

Where is urologytimes.com located?urologytimes.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top urologytimes.com News

Johnson & Johnson (NYSE: JNJ) Gets FDA OK; AKEEGA Delays BRCA2 mCSPC Progress 59 Percent

United States · United States

Johnson & Johnson (NYSE: JNJ) Gets FDA OK; AKEEGA Delays BRCA2 mCSPC Progress 59 Percent

61% Center coverage: 36 sources

FDA clears expanded use of AKEEGA as the first PARP-based precision combo for BRCA2-mutated mCSPC, cutting progression or death 54 percent and delaying symptoms 59 percent in Phase 3.See the Story

FDA Approves First New Antibiotics to Treat Gonorrhea in Decades

FDA · United States

FDA Approves First New Antibiotics to Treat Gonorrhea in Decades

95% Center coverage: 22 sources

FDA approves zoliflodacin (Nuzolvence) and gepotidacin (Blujepa), oral treatments for urogenital gonorrhea that expand options as drug resistance rises See the Story

FDA Approves the ProVee System - the First of a New Generation of Prostatic Urethral Stents for Treatment of BPH

Dublin, Ireland · Dublin

FDA Approves the ProVee System - the First of a New Generation of Prostatic Urethral Stents for Treatment of BPH

58% Center coverage: 12 sources

DUBLIN, Dec. 9, 2025 /PRNewswire/ -- ProVerum Limited, a medical device company focused on innovative, safe and effective solutions for treating benign prostatic hyperplasia (BPH), today announced it has received FDA approval for its ProVee® System for BPH.See the Story

Breaking News Topics Related to urologytimes.com